Update on the RT0001 study: In August 2015, Retrotope launched a Phase 1 study of RT0001 in individuals with FA, ages 18-50 years. This study is enrolling two dose cohorts. The first dose cohort has been fully screened enrolled in the protocol. We anticipate beginning the second dose cohort of 9 individuals in February 2016. Thank you to everyone in the FA community who is participating in the study.
For more information about this trial and sites participating visit, www.curefa.org/active-clinical-trials.